Vitiligo epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(11 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Vitiligo is a worldwide spread disease that affects around 1% of the total world population.  Both male and female are equally affected and a half of patients are diagnosed under the age of 20.
Autoimmune diseases and a family history of vitiligo are considered risk factors for developing this condition. A patient that has a relative with vitiligo has an 18 fold increased risk of developing the disease and having an earlier onset of the disease.


==Epidemiology==
==Epidemiology==


===Prevalence===
===Prevalence===
* The prevalence of vitiligo is about 1% of the total worldwide population.
* The prevalence of vitiligo is 1,000/100,000 (1%) of the population.
* This varies among geographical areas and age groups, from 0.1% up to more than 2%.<ref>{{Cite journal
* The prevalence varies from 100/100,000 (0.1%) up to more than 2,000/100,000 (2%) depending upon the country and age group.<ref>{{Cite journal
  | author = [[Christian Kruger]] & [[Karin Uta Schallreuter]]
  | author = [[Christian Kruger]] & [[Karin Uta Schallreuter]]
  | title = A review of the worldwide prevalence of vitiligo in children/adolescents and adults
  | title = A review of the worldwide prevalence of vitiligo in children/adolescents and adults
Line 22: Line 22:
  | pmid = 22458952
  | pmid = 22458952
}}</ref>
}}</ref>
* Higher prevalence has been found in countries like India, Romania, Uzbekistan and China.<ref>{{Cite journal
* A higher prevalence has been observed in India, Romania, Uzbekistan and China.<ref>{{Cite journal
  | author = [[Christian Kruger]] & [[Karin Uta Schallreuter]]
  | author = [[Christian Kruger]] & [[Karin Uta Schallreuter]]
  | title = A review of the worldwide prevalence of vitiligo in children/adolescents and adults
  | title = A review of the worldwide prevalence of vitiligo in children/adolescents and adults
Line 50: Line 50:


===Gender===
===Gender===
* While the majority of reports state that both sexes are equally affected,<ref>{{Cite journal
* While the majority of studies state that both sexes are equally affected,<ref>{{Cite journal
  | author = [[Virendra N. Sehgal]] & [[Govind Srivastava]]
  | author = [[Virendra N. Sehgal]] & [[Govind Srivastava]]
  | title = Vitiligo: compendium of clinico-epidemiological features
  | title = Vitiligo: compendium of clinico-epidemiological features
Line 60: Line 60:
  | month = May-June
  | month = May-June
  | pmid = 17558045
  | pmid = 17558045
}}</ref> some studies report a higher incidence in young women.<ref>{{Cite journal
}}</ref> some studies report a higher incidence of vitiligo in young women.<ref>{{Cite journal
| author = [[Asem Alkhateeb]], [[Pamela R. Fain]], [[Anthony Thody]], [[Dorothy C. Bennett]] & [[Richard A. Spritz]]
| title = Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families
| journal = [[Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society]]
| volume = 16
| issue = 3
| pages = 208–214
| year = 2003
| month = June
| pmid = 12753387
}}</ref><ref>{{Cite journal
  | author = [[Kyriakos P. Kyriakis]], [[Ioulios Palamaras]], [[Efrosyni Tsele]], [[Charalambos Michailides]] & [[Sofia Terzoudi]]
  | author = [[Kyriakos P. Kyriakis]], [[Ioulios Palamaras]], [[Efrosyni Tsele]], [[Charalambos Michailides]] & [[Sofia Terzoudi]]
  | title = Case detection rates of vitiligo by gender and age
  | title = Case detection rates of vitiligo by gender and age
Line 72: Line 82:
  | pmid = 19261030
  | pmid = 19261030
}}</ref>
}}</ref>
* Females are diagnosed earlier than men.
* Females are diagnosed at a younger age than men.


===Race===
===Race===
* There is no difference between races, but in dark skin patients it is more noticed and has a higher psychological impact.
* There is no difference in the prevalence among races.
* The disease is more often noticed in dark skin patients, and may have a greater psychological impact in dark skin patients.


==References==
==References==

Latest revision as of 13:30, 27 June 2014

Vitiligo Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vitiligo from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Case Studies

Case #1

Vitiligo epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vitiligo epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vitiligo epidemiology and demographics

CDC on Vitiligo epidemiology and demographics

Vitiligo epidemiology and demographics in the news

Blogs on Vitiligo epidemiology and demographics

Directions to Hospitals Treating Vitiligo

Risk calculators and risk factors for Vitiligo epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

Autoimmune diseases and a family history of vitiligo are considered risk factors for developing this condition. A patient that has a relative with vitiligo has an 18 fold increased risk of developing the disease and having an earlier onset of the disease.

Epidemiology

Prevalence

  • The prevalence of vitiligo is 1,000/100,000 (1%) of the population.
  • The prevalence varies from 100/100,000 (0.1%) up to more than 2,000/100,000 (2%) depending upon the country and age group.[1]
  • A higher prevalence has been observed in India, Romania, Uzbekistan and China.[2]

Age

  • 50% of patients with vitiligo are diagnosed before the age of 20. [3]

Gender

  • While the majority of studies state that both sexes are equally affected,[4] some studies report a higher incidence of vitiligo in young women.[5][6]
  • Females are diagnosed at a younger age than men.

Race

  • There is no difference in the prevalence among races.
  • The disease is more often noticed in dark skin patients, and may have a greater psychological impact in dark skin patients.

References

  1. Christian Kruger & Karin Uta Schallreuter (2012). "A review of the worldwide prevalence of vitiligo in children/adolescents and adults". International journal of dermatology. 51 (10): 1206–1212. doi:10.1111/j.1365-4632.2011.05377.x. PMID 22458952. Unknown parameter |month= ignored (help)
  2. Christian Kruger & Karin Uta Schallreuter (2012). "A review of the worldwide prevalence of vitiligo in children/adolescents and adults". International journal of dermatology. 51 (10): 1206–1212. doi:10.1111/j.1365-4632.2011.05377.x. PMID 22458952. Unknown parameter |month= ignored (help)
  3. Virendra N. Sehgal & Govind Srivastava (2007). "Vitiligo: compendium of clinico-epidemiological features". Indian journal of dermatology, venereology and leprology. 73 (3): 149–156. PMID 17558045. Unknown parameter |month= ignored (help)
  4. Virendra N. Sehgal & Govind Srivastava (2007). "Vitiligo: compendium of clinico-epidemiological features". Indian journal of dermatology, venereology and leprology. 73 (3): 149–156. PMID 17558045. Unknown parameter |month= ignored (help)
  5. Asem Alkhateeb, Pamela R. Fain, Anthony Thody, Dorothy C. Bennett & Richard A. Spritz (2003). "Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families". Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society. 16 (3): 208–214. PMID 12753387. Unknown parameter |month= ignored (help)
  6. Kyriakos P. Kyriakis, Ioulios Palamaras, Efrosyni Tsele, Charalambos Michailides & Sofia Terzoudi (2009). "Case detection rates of vitiligo by gender and age". International journal of dermatology. 48 (3): 328–329. doi:10.1111/j.1365-4632.2009.03770.x. PMID 19261030. Unknown parameter |month= ignored (help)

Template:WH Template:WS